Curcumin (BCM-95 / Theracurmin) — Research Protocol
⚠️ RESEARCH SUMMARY — NOT A TREATMENT PROTOCOL. Discuss all findings with your healthcare provider.
Published research on bioavailability-enhanced curcumin formulations has investigated their potential in various conditions. Standard curcumin powder has <1% bioavailability. Dosing regimens in published literature vary by formulation. This page summarizes published research protocols. It is not a guide for self-treatment. Discuss any treatment decisions with your physician.
Research Dosing (from Published Studies)
| Context | Dose | Route | Frequency | Notes |
|---|---|---|---|---|
| Neuroinflammation / Alzheimer's (small RCT) | Dosing regimens in published literature vary — consult the cited studies for details | Oral | See cited trial | A small RCT reported changes in memory scores and amyloid/tau PET signals over 18 months. Published studies have investigated various dosing approaches. Results require replication in larger trials. |
| Cancer adjunctive (Phase II) | Dosing regimens in published literature vary — consult the cited studies for details | Oral | See cited trial | Phase II trials in colorectal and pancreatic cancer have investigated curcumin alongside standard chemotherapy. Published studies have investigated various dosing approaches. |
| Anti-inflammatory (general research) | Dosing regimens in published literature vary — consult the cited studies for details | Oral | See cited studies | Research has investigated piperine co-administration (reported to increase bioavailability) and enhanced formulations (BCM-95 reports 7x standard bioavailability). See cited studies for specific regimens. |
Pharmacokinetics
Standard curcumin: <1% oral bioavailability, extensive first-pass metabolism. Theracurmin: 27x enhanced absorption. BCM-95: 7x enhanced. Meriva (phytosome): 29x enhanced. Half-life 6-8 hours for enhanced formulations.
Safety Profile
Excellent safety profile up to 12g/day (standard) in clinical trials. Enhanced formulations are safe at recommended doses. Mild GI effects (diarrhea, nausea) at high doses. Rare: contact dermatitis. Some concern about iron chelation with chronic high-dose use.
Contraindications
- Gallstones or bile duct obstruction
- Iron deficiency anemia (curcumin chelates iron)
- Before surgery (antiplatelet effects)
- Pregnancy at therapeutic doses (insufficient data)
Monitoring Parameters
- Iron studies if using long-term
- Liver function tests (baseline, 3-month)
- PT/INR if on anticoagulants
- Clinical response assessment